Comparison of DOTA and NODAGA as chelators for 64Cu-labeled immunoconjugates

Nuclear Medicine and Biology

Volumn 42, Issue 2, 2015, Pages 177-183

  Ghosh, Sukhen C ^a   Pinkston, Kenneth L ^a   Robinson, Holly ^a   Harvey, Barrett R ^a   Wilganowski, Nathaniel ^a   Gore, Karen ^a   Sevick Muraca, Eva M ^a   Azhdarinia, Ali ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Antibody; Copper 64; DOTA; EpCAM; NODAGA; PET

Indexed keywords

,1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID MONOCLONAL ANTIBODY CU 64; 1,4,7 TRIAZACYCLONONANE 1 GLUTARIC ACID 4,7 ACETIC ACID MONOCLONAL ANTIBODY 7 CU 64; ANTIBODY CONJUGATE; EPITHELIAL CELL ADHESION MOLECULE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; 1-(1,3-CARBOXYPROPYL)-4,7-CARBOXYMETHYL-1,4,7-TRIAZACYCLONONANE; ACETIC ACID DERIVATIVE; CHELATING AGENT; COPPER; MONOCLONAL ANTIBODY; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG RETENTION; DRUG SYNTHESIS; DRUG UPTAKE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOCHEMISTRY; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DIAGNOSTIC USE; DRUG STABILITY; HUMAN; METABOLISM; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ACETATES; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CHELATING AGENTS; COPPER RADIOISOTOPES; DRUG STABILITY; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMMUNOCONJUGATES; MALE; MICE; TISSUE DISTRIBUTION;

EID: 84921404084     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.09.009     Document Type: Article

References (41)

1. Lutje S., Boerman O.C., van Rij C.M., Sedelaar M., Helfrich W., Oyen W.J., et al. Prospects in radionuclide imaging of prostate cancer. Prostate 2012, 72:1262-1272.
2. 89Zr-7E11 immuno-PET. J Nucl Med 2011, 52:1608-1615.
3. van Rij C.M., Sharkey R.M., Goldenberg D.M., Frielink C., Molkenboer J.D., Franssen G.M., et al. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody. J Nucl Med 2011, 52:1601-1607.
4. Olafsen T., Gu Z., Sherman M.A., Leyton J.V., Witkosky M.E., Shively J.E., et al. Targeting, maging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 2007, 30:396-405.
5. Wadas T.J., Wong E.H., Weisman G.R., Anderson C.J. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des 2007, 13:3-16.
6. Wadas T.J., Anderson C.J. Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nat Protoc 2006, 1:3062-3068.
7. 64Cu-DOTA-conatumumab: a PET tracer for in vivo imaging of death receptor 5. J Nucl Med 2011, 52:942-949.
8. 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate 2010, 70:1413-1421.
9. Niu G., Li Z., Cao Q., Chen X. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging 2009, 36:1510-1519.
10. Bass L.A., Wang M., Welch M.J., Anderson C.J. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem 2000, 11:527-532.
11. Boswell C.A., Sun X., Niu W., Weisman G.R., Wong E.H., Rheingold A.L., et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 2004, 47:1465-1474.
12. 64Cu for tumor imaging and therapy. J Nucl Med 2003, 44:1284-1292.
13. Kumar S.R., Gallazzi F.A., Ferdani R., Anderson C.J., Quinn T.P., Deutscher S.L. In vitro and in vivo evaluation of (64)Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas. Cancer Biother Radiopharm 2010, 25:693-703.
14. Ciesienski K.L., Yang Y., Ay I., Chonde D.B., Loving G.S., Rietz T.A., et al. Fibrin-targeted PET probes for the detection of thrombi. Mol Pharm 2013, 10:1100-1110.
15. 64Cu-labeled E. coli heat-stable enterotoxin analogues for PET imaging of colorectal cancer. Bioconjug Chem 2010, 21:1171-1176.
16. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer. Nucl Med Biol 2012, 39:377-387.
17. 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med 2011, 52:1110-1118.
18. Blasi F., Oliveira B.L., Rietz T.A., Rotile N.J., Day H., Looby R.J., et al. Effect of chelate type and radioisotope on the imaging efficacy of four fibrin-specific PET probes. J Nucl Med 2014, 52:1157-1163.
19. 111In using a maleimido derivative of NODAGA. Nucl Med Biol 2012, 39:518-529.
20. Altai M., Strand J., Rosik D., Selvaraju R.K., Eriksson Karlstrom A., Orlova A., et al. Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with (68)Ga and (111)In via maleimido derivatives of DOTA and NODAGA. Bioconjug Chem 2013, 24:1102-1109.
21. Hall M.A., Kwon S., Robinson H., Lachance P.A., Azhdarinia A., Ranganathan R., et al. Imaging prostate cancer lymph node metastases with a multimodality contrast agent. Prostate 2012, 72:129-146.
22. Hall M.A., Pinkston K.L., Wilganowski N., Robinson H., Ghosh P., Azhdarinia A., et al. Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET/CT and NIRF. J Nucl Med 2012, 53:1427-1437.
23. Poczatek R.B., Myers R.B., Manne U., Oelschlager D.K., Weiss H.L., Bostwick D.G., et al. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 1999, 162:1462-1466.
24. Gao P., Pinkston K.L., Wilganowski N., Robinson H., Azhdarinia A., Zhu B., et al. Deglycosylation of mAb by EndoS for improved molecular imaging. Mol Imaging Biol 2014, [Epub ahead of print].
25. Kume M., Carey P.C., Gaehle G., Madrid E., Voller T., Margenau W., et al. A semi-automated system for the routine production of copper-64. Appl Radiat Isot 2012, 70:1803-1806.
26. Ghosh S.C., Ghosh P., Wilganowski N., Robinson H., Hall M.A., Dickinson G., et al. Multimodal chelation platform for near-infrared fluorescence/nuclear imaging. J Med Chem 2013, 56:406-416.
27. Ferreira C.L., Yapp D.T., Crisp S., Sutherland B.W., Ng S.S., Gleave M., et al. Comparison of bifunctional chelates for (64)Cu antibody imaging. Eur J Nucl Med Mol Imaging 2010, 37:2117-2126.
28. Liu S., Li Z., Conti P.S. Development of multi-functional chelators based on sarcophagine cages. Molecules 2014, 19:4246-4255.
29. Zeng D., Ouyang Q., Cai Z., Xie X.Q., Anderson C.J. New cross-bridged cyclam derivative CB-TE1K1P, an improved bifunctional chelator for copper radionuclides. Chem Commun (Camb) 2014, 50:43-45.
30. Dearling J.L., Voss S.D., Dunning P., Snay E., Fahey F., Smith S.V., et al. Imaging cancer using PET-the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody. Nucl Med Biol 2011, 38:29-38.
31. 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS One 2011, 6:e28005.
32. Dumont R.A., Deininger F., Haubner R., Maecke H.R., Weber W.A., Fani M. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of alpha(nu)beta(3) integrin expression and facile radiosynthesis. J Nucl Med 2011, 52:1276-1284.
33. Wadas T.J., Wong E.H., Weisman G.R., Anderson C.J. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 2010, 110:2858-2902.
34. Giragossian C., Clark T., Piche-Nicholas N., Bowman C.J. Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics. Curr Drug Metab 2013, 14:764-790.
35. Baeuerle P.A., Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007, 96:417-423.
36. Went P., Vasei M., Bubendorf L., Terracciano L., Tornillo L., Riede U., et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006, 94:128-135.
37. Munz M., Murr A., Kvesic M., Rau D., Mangold S., Pflanz S., et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int 2010, 10:44.
38. Olafsen T., Wu A.M. Antibody vectors for imaging. Semin Nucl Med 2010, 40:167-181.
39. Olafsen T., Kenanova V.E., Sundaresan G., Anderson A.L., Crow D., Yazaki P.J., et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 2005, 65:5907-5916.
40. Wu A.M., Yazaki P.J., Tsai S., Nguyen K., Anderson A.L., McCarthy D.W., et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A 2000, 97:8495-8500.
41. 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. EJNMMI Res 2011, 1:15.